{"id":"W4304474516","doi":"10.1200/jco.21.02508","title":"Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":490,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Center for Advancing Translational Sciences; National Institute for Health and Care Research; Cancer Research UK","keywords":"Pembrolizumab; Medicine; Internal medicine; Hazard ratio; Oncology; Head and neck squamous-cell carcinoma; Chemotherapy; Interquartile range; Cetuximab; Head and neck cancer; Population; Radiation therapy; Cancer; Immunotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002767106,0.0001774307,0.002191789,0.0001244987,0.00009651981,0.000004271195,0.0001967862,0.00006852365,0.0001214105],"category_scores_gemma":[0.0008644863,0.00008208537,0.000163123,0.0004018406,0.0002226424,0.00004572456,0.0001210912,0.001193971,3.965871e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001894046,"about_ca_system_score_gemma":0.002440582,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001570123,"about_ca_topic_score_gemma":0.001376539,"domain_scores_codex":[0.9956269,0.0009804969,0.002375758,0.0002547912,0.0005190148,0.0002430553],"domain_scores_gemma":[0.9963793,0.001302842,0.001638405,0.0002585311,0.0002302458,0.0001906552],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7308723,0.03033871,0.1816182,0.0001041852,0.000401916,0.002106203,0.006749754,0.00002427741,0.00009647038,0.000002780914,0.006047807,0.04163741],"study_design_scores_gemma":[0.3757208,0.3017278,0.2872694,0.00009657333,0.0007750919,0.0007955179,0.005804202,0.0002611465,0.00009852204,0.00001264173,0.0272834,0.0001549693],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925852,0.0005744791,0.000003674194,0.004996826,0.0004768179,0.0008244427,0.00001630057,0.000004626566,0.0005175855],"genre_scores_gemma":[0.9975681,0.0001889816,0.0003769204,0.001176402,0.0001524087,0.00001984457,0.000001550827,0.00001924723,0.000496525],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3551515,"threshold_uncertainty_score":0.5187277,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1305832615829773,"score_gpt":0.4718791313295498,"score_spread":0.3412958697465725,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}